$VTAK
Catheter Precision, Inc.

2023 Q1 Form 10-K Financial Statement

#000156459023004567 Filed on March 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $85.00K $0.00 $14.00K
YoY Change 844.44% -100.0% -36.36%
Cost Of Revenue $10.00K $0.00 $161.0K
YoY Change -89.47% -100.0% -89.68%
Gross Profit $75.00K $0.00 -$147.0K
YoY Change -187.21% -100.0% -90.44%
Gross Profit Margin 88.24% -1050.0%
Selling, General & Admin $8.833M $7.958M $16.25M
YoY Change 283.71% 89.93% 5.01%
% of Gross Profit 11777.33%
Research & Development $240.0K $154.0K $6.392M
YoY Change -92.3% -95.87% -47.83%
% of Gross Profit 320.0%
Depreciation & Amortization $1.444M $25.00K $200.0K
YoY Change 1344.0% -92.06% -80.0%
% of Gross Profit 1925.33%
Operating Expenses $10.47M $8.112M $26.81M
YoY Change 93.34% 2.4% -3.3%
Operating Profit -$10.40M -$8.112M -$26.96M
YoY Change 88.95% -1.84% -7.88%
Interest Expense $69.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $15.00K $59.00K $99.00K
YoY Change 87.5% -410.53% -95.07%
Pretax Income -$66.40M -$8.156M -$26.86M
YoY Change 1108.37% -1.53% -1.45%
Income Tax $0.00 $3.000K $3.000K
% Of Pretax Income
Net Earnings -$67.20M -$8.159M -$26.87M
YoY Change 1122.93% -1.54% 7.16%
Net Earnings / Revenue -79058.82% -191892.86%
Basic Earnings Per Share -$25.98
Diluted Earnings Per Share -$24.65 -$3.83 -$25.98
COMMON SHARES
Basic Shares Outstanding 4.984M 2.161M 1.034M
Diluted Shares Outstanding 1.034M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.22M $15.86M $15.86M
YoY Change -30.78% 5.41% 5.41%
Cash & Equivalents $12.22M $15.90M $15.86M
Short-Term Investments
Other Short-Term Assets $388.0K $977.0K $977.0K
YoY Change -69.62% -5.79% -5.79%
Inventory $70.00K $0.00 $0.00
Prepaid Expenses
Receivables $80.00K $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.76M $16.84M $16.84M
YoY Change -36.26% -1.48% -1.48%
LONG-TERM ASSETS
Property, Plant & Equipment $185.0K $0.00 $0.00
YoY Change -88.84% -100.0% -100.0%
Goodwill $0.00 $0.00
YoY Change
Intangibles $1.700M
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.000K $0.00 $0.00
YoY Change -86.11% -100.0% -100.0%
Total Long-Term Assets $35.75M $0.00 $0.00
YoY Change 857.76% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $12.76M $16.84M $16.84M
Total Long-Term Assets $35.75M $0.00 $0.00
Total Assets $48.51M $16.84M $16.84M
YoY Change 104.27% -20.0% -20.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $580.0K $92.00K $92.00K
YoY Change -50.47% -90.69% -90.69%
Accrued Expenses $3.873M $7.484M $7.484M
YoY Change 70.39% 81.69% 70.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.453M $7.576M $7.576M
YoY Change 19.22% 40.56% 40.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.193M $0.00 $0.00
YoY Change 330.3% -100.0% -100.0%
Total Long-Term Liabilities $8.193M $0.00 $0.00
YoY Change 330.3% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.453M $7.576M $7.576M
Total Long-Term Liabilities $8.193M $0.00 $0.00
Total Liabilities $12.65M $7.576M $7.576M
YoY Change 124.26% 2.78% 2.78%
SHAREHOLDERS EQUITY
Retained Earnings -$205.1M
YoY Change 15.05%
Common Stock $214.4M
YoY Change 11.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.86M $9.260M $9.260M
YoY Change
Total Liabilities & Shareholders Equity $48.51M $16.84M $16.84M
YoY Change 104.27% -20.0% -20.0%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$67.20M -$8.159M -$26.87M
YoY Change 1122.93% -1.54% 7.16%
Depreciation, Depletion And Amortization $1.444M $25.00K $200.0K
YoY Change 1344.0% -92.06% -80.0%
Cash From Operating Activities -$12.05M -$3.025M -$22.60M
YoY Change 40.15% -47.03% -18.12%
INVESTING ACTIVITIES
Capital Expenditures $37.00K $17.00K $17.00K
YoY Change -141.46% -93.58%
Acquisitions -$15.00K
YoY Change
Other Investing Activities $15.00K $38.00K $38.00K
YoY Change -5.0% -99.07%
Cash From Investing Activities -$22.00K $21.00K $21.00K
YoY Change -2200.0% -99.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.434M 5.206M 23.36M
YoY Change -24.53% 3592.2% 56.14%
NET CHANGE
Cash From Operating Activities -12.05M -3.025M -22.60M
Cash From Investing Activities -22.00K 21.00K 21.00K
Cash From Financing Activities 8.434M 5.206M 23.36M
Net Change In Cash -3.641M 2.202M 814.0K
YoY Change -239.66% -139.53% -109.19%
FREE CASH FLOW
Cash From Operating Activities -$12.05M -$3.025M -$22.60M
Capital Expenditures $37.00K $17.00K $17.00K
Free Cash Flow -$12.09M -$3.042M -$22.62M
YoY Change 40.58% -46.35% -18.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1981000
CY2022Q4 us-gaap Liabilities
Liabilities
7576000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
92000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7484000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
988000
CY2021 us-gaap Gross Profit
GrossProfit
-1538000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16250000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15475000
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Trading Symbol
TradingSymbol
RMED
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
9900000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q4 us-gaap Liabilities
Liabilities
7371000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191945000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178272000
CY2022 dei Entity File Number
EntityFileNumber
001-38677
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Mill
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
SC
CY2022 dei City Area Code
CityAreaCode
973
CY2022 dei Local Phone Number
LocalPhoneNumber
691-2000
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
977000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16836000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1809000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2110000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
197000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-150000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
204000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
192000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
335000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15859000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15045000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21000
CY2021 us-gaap Depreciation
Depreciation
1000000.0
CY2022 dei Entity Registrant Name
EntityRegistrantName
Ra Medical Systems, Inc.
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2161000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2161000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
214397000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205137000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9260000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16836000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
140000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13673000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21044000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22000
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
29708
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
283000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5390000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4984093
CY2022 dei Auditor Firm
AuditorFirmId
200
CY2022 dei Auditor Name
AuditorName
HASKELL & WHITE LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001716621
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
All full-time employees are eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company makes matching contributions based on?100%?of each employee?s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to?4%?of the employee?s eligible compensation.
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3661826
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1670 Highway 160 West, Suite 205
CY2022 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 us-gaap Inventory Net
InventoryNet
986000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1037000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
17089000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36000
CY2022Q4 us-gaap Assets
Assets
16836000
CY2021Q4 us-gaap Assets
Assets
21044000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4119000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7576000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
140000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
161000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1560000
CY2022 us-gaap Gross Profit
GrossProfit
-147000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6392000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12253000
CY2022 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
4172000
CY2022 us-gaap Operating Expenses
OperatingExpenses
26814000
CY2021 us-gaap Operating Expenses
OperatingExpenses
27728000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-26961000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-29266000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2023000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
99000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2009000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26862000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27257000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-26865000
CY2021 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-27261000
CY2021 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
2191000
CY2021 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
2191000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26865000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25070000
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-25.98
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-25.98
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-269.91
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-269.91
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
21.69
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
21.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.98
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.98
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-248.22
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-248.22
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1034000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1034000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21147000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15153000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
132000
CY2021 rmed Common Stock Issued Pursuant To The Vesting Of Restricted Stock Units And Employee Stock Purchase Plan
CommonStockIssuedPursuantToTheVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlan
74000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2237000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-25070000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13673000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11638000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4658000
CY2022 rmed Exercise Of Warrants
ExerciseOfWarrants
5704000
CY2022 rmed Common Stock Issued Pursuant To The Vesting Of Restricted Stock Units And Employee Stock Purchase Plan
CommonStockIssuedPursuantToTheVestingOfRestrictedStockUnitsAndEmployeeStockPurchasePlan
5000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
447000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26865000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9260000
CY2022 us-gaap Profit Loss
ProfitLoss
-26865000
CY2021 us-gaap Profit Loss
ProfitLoss
-25070000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
2943000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
447000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2237000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
421000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1565000
CY2022 rmed Gain On Write Off Of Right Of Use Asset And Liability
GainOnWriteOffOfRightOfUseAssetAndLiability
126000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-44000
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
550000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
21000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
47000
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3473000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2023000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-879000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
627000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2009000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-390000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-234000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-234000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-356000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22568000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27625000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
38000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
594000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
265000
CY2021 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
3700000
CY2021 rmed Payment Of Fees Related To Sale Of Discontinued Operations
PaymentOfFeesRelatedToSaleOfDiscontinuedOperations
227000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3802000
CY2022 rmed Proceeds From Issuance Of Common Stock And Warrants Net Fees Withheld
ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld
18906000
CY2021 rmed Proceeds From Issuance Of Common Stock And Warrants Net Fees Withheld
ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld
15528000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5704000
CY2022 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
1254000
CY2021 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
375000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
74000
CY2021 rmed Repayment Of Equipment Financing
RepaymentOfEquipmentFinancing
265000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23361000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14962000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
814000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8861000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15045000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23906000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15859000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15045000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1356000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On September 20, 2022, the Company’s board of directors approved a reverse stock split ratio of 1-for-50 (the “Reverse Stock Split”).
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68200000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1400000
CY2022Q2 us-gaap Severance Costs1
SeveranceCosts1
600000
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
300000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15900000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22600000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205100000
CY2022Q4 rmed Accrued Expenses Related To Merger With Catheter
AccruedExpensesRelatedToMergerWithCatheter
7500000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="color:#000000;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The</span> preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The Company’s financial statements are based upon a number of estimates including, but not limited to, allowance for credit losses, evaluation of impairment of assets, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, evaluation of probable loss contingencies and fair value of equity awards granted.</p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 rmed Disposal Group Including Discontinued Operation Interest Income Expense Net
DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpenseNet
-94000
CY2021 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-1282000
CY2021 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3473000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
131000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
84000
CY2022 rmed Provision For Credit Losses Continuing Operations
ProvisionForCreditLossesContinuingOperations
21000
CY2021 rmed Provision For Credit Losses Continuing Operations
ProvisionForCreditLossesContinuingOperations
47000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
152000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
131000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2022 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk that arise from financial instruments exist for groups of customers or counterparties when they have similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions described below. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash equivalent balances maintained in excess of Federal Depository Insurance Corporation limits, and accounts receivable which have no collateral or security. The Company monitors the financial condition of the banks in which it currently has deposits. The Company has not experienced any significant losses in this respect and believes that it is not exposed to any significant related risk. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exposure to losses on accounts receivable is dependent upon the individual customer’s financial condition. The Company monitors its exposure to credit losses and reserves for those accounts receivable that it deems to be not collectible.</p>
CY2022 rmed Capitalized Contract Cost Amortization Period1
CapitalizedContractCostAmortizationPeriod1
P1Y
CY2021 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
2600000
CY2021 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
2290000
CY2021 rmed Gros Income Loss From Discontinued Operations
GrosIncomeLossFromDiscontinuedOperations
310000
CY2021 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
1498000
CY2021 rmed Disposal Group Including Discontinued Operation Operating Income Loss Gross
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLossGross
-1188000
CY2021 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2191000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1700000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
911000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
70000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5000
CY2021Q4 us-gaap Inventory Net
InventoryNet
986000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4658000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2849000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1809000
CY2022 us-gaap Depreciation
Depreciation
200000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1500000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5195000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1345000
CY2022Q4 rmed Accrued Offering Costs Current
AccruedOfferingCostsCurrent
1356000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
369000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2004000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
192000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
372000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
575000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7484000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4119000
CY2022 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
3000
CY2021 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
9000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000
CY2021 rmed Operating Lease Number Of Leases
OperatingLeaseNumberOfLeases
2
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
200000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
400000
CY2022 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1150669
CY2022 rmed Common Stock Capital Shares Weighted Average Exercise Price
CommonStockCapitalSharesWeightedAverageExercisePrice
33.67
CY2022 rmed Contract Termination Fees Related To Restructuring
ContractTerminationFeesRelatedToRestructuring
319000
CY2022 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
4172000
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
900000
CY2022 rmed Impairment And Inventory Obsolescence Charges And Write Off Of Prepaid Research And Development Supplies
ImpairmentAndInventoryObsolescenceChargesAndWriteOffOfPrepaidResearchAndDevelopmentSupplies
2900000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
447000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2054000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1548000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
1000000
CY2022 us-gaap Severance Costs1
SeveranceCosts1
910000
CY2022 rmed Prepaid Expenses Related To Restructuring
PrepaidExpensesRelatedToRestructuring
395000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 rmed Effective Income Tax Rate Reconciliation Net Operating Loss Limitation
EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation
0.426
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.013
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.026
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
0.017
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.223
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.214
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4000
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
3000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
4000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
518000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9706000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5162000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4605000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1528000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
95000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
169000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
35000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
56000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
1355000
CY2021Q4 rmed Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
556000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
399000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
71000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8694000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15562000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
348000
CY2021Q4 rmed Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
518000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
866000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8694000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14696000
CY2022 rmed Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2030
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 rmed Income Tax Examination Years Under Examination
IncomeTaxExaminationYearsUnderExamination
2018 and later
CY2022 us-gaap General Discussion Of Pension And Other Postretirement Benefits
GeneralDiscussionOfPensionAndOtherPostretirementBenefits
In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (“401(k) Plan”). Under the terms of the 401(k) Plan, all full-time employees were eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company made matching contributions based on 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employee’s eligible compensation.
CY2022 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
200000
CY2021 us-gaap Defined Contribution Plan Administrative Expenses
DefinedContributionPlanAdministrativeExpenses
300000
CY2022 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
355000
CY2022 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-41559000
CY2022 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-22.30
CY2022 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-22.30

Files In Submission

Name View Source Status
0001564590-23-004567-index-headers.html Edgar Link pending
0001564590-23-004567-index.html Edgar Link pending
0001564590-23-004567.txt Edgar Link pending
0001564590-23-004567-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gb4augzxvqxh000001.jpg Edgar Link pending
gb4augzxvqxh000002.jpg Edgar Link pending
gb4augzxvqxh000003.jpg Edgar Link pending
gb4augzxvqxh000004.jpg Edgar Link pending
gb4augzxvqxh000005.jpg Edgar Link pending
gkjax5s40l4i000001.jpg Edgar Link pending
glyiexezausa000001.jpg Edgar Link pending
gtrf0kgotfpm000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmed-10k_20221231.htm Edgar Link pending
rmed-20221231.xsd Edgar Link pending
rmed-ex10161_639.htm Edgar Link pending
rmed-ex10271_642.htm Edgar Link pending
rmed-ex10272_641.htm Edgar Link pending
rmed-ex10273_640.htm Edgar Link pending
rmed-ex1028_822.htm Edgar Link pending
rmed-20221231_pre.xml Edgar Link unprocessable
rmed-10k_20221231_htm.xml Edgar Link completed
rmed-ex10291_645.htm Edgar Link pending
rmed-ex10292_643.htm Edgar Link pending
rmed-ex1029_644.htm Edgar Link pending
rmed-ex10301_648.htm Edgar Link pending
rmed-ex10302_821.htm Edgar Link pending
rmed-ex10311_647.htm Edgar Link pending
rmed-ex1031_646.htm Edgar Link pending
rmed-ex10321_1165.htm Edgar Link pending
rmed-ex1032_650.htm Edgar Link pending
rmed-ex211_649.htm Edgar Link pending
rmed-ex231_7.htm Edgar Link pending
rmed-ex311_10.htm Edgar Link pending
rmed-ex312_12.htm Edgar Link pending
rmed-ex321_11.htm Edgar Link pending
rmed-ex322_9.htm Edgar Link pending
rmed-ex42_6.htm Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
rmed-20221231_cal.xml Edgar Link unprocessable
rmed-20221231_def.xml Edgar Link unprocessable
rmed-20221231_lab.xml Edgar Link unprocessable